Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Efficacy of Osteopathic Manipulative Techniques With Progressive Pulmonary Fibrosis Patients

NCT07548216 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-05
Last updated
2026-04-23

Condition(s) studied

Osteopathic Manipulative Treatment

Investigational drug(s) / intervention(s)

osteopathic manipulative techniquesconventional chest physiotherapy

osteopathic manipulative techniques: for 4 weeks , 2 sessions per week

conventional chest physiotherapy: for 4 weeks , 3 sessions per week

Study summary

The goal of this clinical trial is to learn if osteopathic manipulative techniques add benefits for treatment of patients with progressive pulmonary fibrosis. The main questions it aims to answer are :

Could osteopathic manipulative techniques add benefits for treatment of patients with progressive pulmonary fibrosis? Researchers will compare osteopathic manipulative techniques with chest physiotherapy to chest physiotherapy alone to see if osteopathic manipulative techniques works to treat progressive pulmonary fibrosis.

Participants will:

Take osteopathic manipulative techniques 2 days a week for 4 weeks and chest physiotherapy 3 days a week for 4 weeks

Eligibility

Sex
ALL
Min age
19 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Their age \> 18. * Both sexes. * Patients without excerbations. * FVC of the patient \<50% . * FEV1/ FVC of the patient \<50%. * Hemodynamic stable. * Conscious and cooperative. * Are able to participate in training actively. Exclusion Criteria: * Patients with acute excerbations. * Acute or Uncontrolled Infections. * Active Malignancy. * Chest deformity

Primary outcome measure(s)

  • pulmonary function test - FVC — preintervention , post intervention after 4 weeks
    FVC
  • pulmonary function test - FEV — pre intervention , post intervention after 4 weeks
    FEV
  • pulmonary function test - FEV/FVC — pre intervention , post intervention after 4 weeks
    FEV/FVC

Trial sites (1)

FacilityCityRegionStatus
Hospital of Beni Suef University Banī Suwayf Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07548216 on ClinicalTrials.gov ↗ ← All trials in Egypt